CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.
“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”
That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.
